Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Program Helps Hepatitis C Patients
Uncategorized

Program Helps Hepatitis C Patients

By medwebNov 4, 2002
Share
Facebook Twitter Email

November 4, 2002

Program Helps Hepatitis C Patients

BOSTON— A new cognitive behavioral therapy strategy developed by Schering-Plough improves compliance among patients with hepatitis C (HCV) who are receiving the pegylated interferon-based combination therapy Peg-Intron® and Rebetol® (ribavirin), according to a Northwestern University study.

Steven L. Flamm, MD, associate professor of medicine and of surgery at The Feinberg School of Medicine and principal investigator on the study, presented his group’s findings today at the 53rd annual meeting of the American Association for the Study of Liver Disease.

In his presentation, Dr. Flamm showed that HCV patients enrolled in an aggressive side-effect management program including the Schering-Plough patient assistance program BeInCharge are less likely to stop taking Peg-Intron and Rebetol combination therapy in the first 12 weeks of therapy than patients who receive only routine supportive care by their physicians.

Study results also indicated that pegylated interferon-based combination therapy significantly improves physical- and mental health-related quality of life at weeks four and eight of the regimen.

“The next advancement in treatment may be some years down the road. Right now we need to maximize the current standard of care to get better results for patients,” Dr. Flamm said. “This study suggests that a proactive support program can actually contribute to the success of therapy and can therefore lead to increased cures for this often deadly infection.”

BeInCharge is designed to assist patients in managing side effects associated with HCV therapy through the use of educational materials and telephone support by nurses. To date, the program has enrolled more than 55,000 HCV patients.

Some 4 million Americans are infected with HCV, and approximately 70 percent of infected patients go on to develop chronic liver disease, according to the Centers for Disease Control and Prevention. HCV infection contributes to the deaths of an estimated 8,000–10,000 Americans each year.

Treatment for HCV-related disease is expected to exceed $13 billion in the United States for the years 2010 through 2019, according to a recent study.

Education
Share. Facebook Twitter Email

Related Posts

Honors Day Celebrates Student and Faculty Excellence

May 15, 2023

Feinberg Again Ranks Among Top Medical Schools in the Nation

May 11, 2023

Medical Student Event Encourages Aspiring Doctors

Apr 10, 2023

Comments are closed.

Latest News

Largest cell map of human lung reveals insights into disease

Jun 8, 2023

McNally Honored with Walder Award

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023

Developing New Nanoparticle Treatments for Brain Tumors

Jun 6, 2023

Newly Discovered Mechanisms Increase Chemotherapy Resistance in Breast Cancer 

Jun 5, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
ANB05555
ANB08990
ANB09022
ANB09063
ANB09008
ANB08781
ANB08971
ANB09000
ANB08992
ANB09015
ANB09058
ANB09048

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.